Dottie Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dottie Yu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Ram Ayyala
Department of Quantitative and Computational Biology, Dana and David Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, USA
3 shared publications - Serghei Mangul
Małopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland
3 shared publications - Aditya Sarkar
Indian Institute of Technology Mandi
2 shared publications - Anushka Yadav
Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
2 shared publications - Dumitru Ciorba
Department of Computers, Informatics and Microelectronics, Technical University of Moldova, Chisinau, Moldova
2 shared publications Emma Shih
Department of Quantitative and Computational Biology, Dana and David Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, USA
2 shared publications
Latest Publications
- Open Access
- 9 September 2025
- Published by Springer Nature in Genome Biology
- Vol. 26 (1) , 1-19
The systematic assessment of completeness of public metadata accompanying omics studies in the Gene Expression Omnibus data repository
Recent advances in high-throughput sequencing technologies have enabled the collection and sharing of a massive amount of omics data, along with its associated metadata—descriptive information that contextualizes the data, including phenotypic traits and experimental design. Enhancing metadata availability is critical to ensure data reusability and reproducibility and to facilitate novel biomedical discoveries through effective data reuse. Yet, incomplete metadata accompanying public omics data may hinder reproducibility and reusability and limit secondary analyses. Our study assesses the completeness of metadata in over 253 scientific studies, covering more than 164,000 samples from both human and non-human mammalian studies. We find that over 25% of critical metadata are omitted, with only 74.8% of relevant phenotypes available in publications or public repositories. Notably, public repositories alone contain 62% of the phenotypes, surpassing the textual content of publications by 3.5%. Only 11.5% of studies completely shared all phenotypes, while 37.9% shared less than 40% of the phenotypes. Additionally, studies with non-human samples are more likely to include complete metadata compared to human studies. Similar trends are observed in an extended dataset comprising 61,000 studies and 2.1 million samples from the Gene Expression Omnibus (GEO) data repository. These findings highlight significant gaps in metadata sharing, underscoring the need for standardized practices to improve metadata availability. Enhanced metadata reporting would foster data reusability, support better-informed decision-making, and promote reproducible research across the biomedical field.
- 9 September 2025
- Published by Springer Nature in Genome Biology
- Vol. 26 (1) , 1-19
Open AccessThe systematic assessment of completeness of public metadata accompanying omics studies in the Gene Expression Omnibus data repository
Recent advances in high-throughput sequencing technologies have enabled the collection and sharing of a massive amount of omics data, along with its associated metadata—descriptive information that contextualizes the data, including phenotypic traits and experimental design. Enhancing metadata availability is critical to ensure data reusability and reproducibility and to facilitate novel biomedical discoveries through effective data reuse. Yet, incomplete metadata accompanying public omics data may hinder reproducibility and reusability and limit secondary analyses. Our study assesses the completeness of metadata in over 253 scientific studies, covering more than 164,000 samples from both human and non-human mammalian studies. We find that over 25% of critical metadata are omitted, with only 74.8% of relevant phenotypes available in publications or public repositories. Notably, public repositories alone contain 62% of the phenotypes, surpassing the textual content of publications by 3.5%. Only 11.5% of studies completely shared all phenotypes, while 37.9% shared less than 40% of the phenotypes. Additionally, studies with non-human samples are more likely to include complete metadata compared to human studies. Similar trends are observed in an extended dataset comprising 61,000 studies and 2.1 million samples from the Gene Expression Omnibus (GEO) data repository. These findings highlight significant gaps in metadata sharing, underscoring the need for standardized practices to improve metadata availability. Enhanced metadata reporting would foster data reusability, support better-informed decision-making, and promote reproducible research across the biomedical field.
- Open Access
A rigorous benchmarking of alignment-based HLA typing algorithms for RNA-seq data
Accurate identification of human leukocyte antigen (HLA) alleles is essential for various clinical and research applications, such as transplant matching and drug sensitivities. Recent advances in RNA-seq technology have made it possible to impute HLA types from high throughput sequencing data, spurring the development of a large number of computational HLA typing tools. However, the relative performance of these tools is unknown, limiting the ability for clinical and biomedical research to make informed choices regarding which tools to use. Here, we rigorously compare the performance of 9 HLA callers on 652 RNA-seq samples across 6 datasets with molecularly defined gold standard. We find that OptiType has the highest accuracy at both low and high resolution with an accuracy above 99%, followed by arcasHLA and seq2HLA with accuracies above 96%. Despite OptiType’s high accuracy, it is only capable of Class I predictions, thereby limiting its application to clinical procedures like transplantation requiring Class II predictions. Furthermore, our findings reveal significant variation in accuracy across each HLA locus, with HLA-A exhibiting the highest accuracy and HLA-DRB1 exhibiting the lowest accuracy. We also find that class II genes are generally more challenging to impute than class I genes, with most typing algorithms capable of making Class I predictions to >97% accuracy whereas the best Class II tool predicts with 94.2% accuracy. Moreover, we identify notable differences in the computational resources necessary to run each tool. We find that the most computationally expensive tools are OptiType and HLA-HD which require 105 and 102 times greater RAM and CPU, respectively, than the least computationally expensive tools, seq2HLA and RNA2HLA. Furthermore, all tools have decreased accuracy for African samples with respect to European samples at four digit resolution. We conclude that RNA-Seq HLA callers are capable of returning high-quality results, but the tools that offer a good balance between accuracy, consistency, and computational expensiveness are yet to be developed.
Open AccessA rigorous benchmarking of alignment-based HLA typing algorithms for RNA-seq data
Accurate identification of human leukocyte antigen (HLA) alleles is essential for various clinical and research applications, such as transplant matching and drug sensitivities. Recent advances in RNA-seq technology have made it possible to impute HLA types from high throughput sequencing data, spurring the development of a large number of computational HLA typing tools. However, the relative performance of these tools is unknown, limiting the ability for clinical and biomedical research to make informed choices regarding which tools to use. Here, we rigorously compare the performance of 9 HLA callers on 652 RNA-seq samples across 6 datasets with molecularly defined gold standard. We find that OptiType has the highest accuracy at both low and high resolution with an accuracy above 99%, followed by arcasHLA and seq2HLA with accuracies above 96%. Despite OptiType’s high accuracy, it is only capable of Class I predictions, thereby limiting its application to clinical procedures like transplantation requiring Class II predictions. Furthermore, our findings reveal significant variation in accuracy across each HLA locus, with HLA-A exhibiting the highest accuracy and HLA-DRB1 exhibiting the lowest accuracy. We also find that class II genes are generally more challenging to impute than class I genes, with most typing algorithms capable of making Class I predictions to >97% accuracy whereas the best Class II tool predicts with 94.2% accuracy. Moreover, we identify notable differences in the computational resources necessary to run each tool. We find that the most computationally expensive tools are OptiType and HLA-HD which require 105 and 102 times greater RAM and CPU, respectively, than the least computationally expensive tools, seq2HLA and RNA2HLA. Furthermore, all tools have decreased accuracy for African samples with respect to European samples at four digit resolution. We conclude that RNA-Seq HLA callers are capable of returning high-quality results, but the tools that offer a good balance between accuracy, consistency, and computational expensiveness are yet to be developed.
- Open Access
The systematic assessment of completeness of public metadata accompanying omics studies in the Gene Expression Omnibus
Recent advances in high-throughput sequencing technologies have made it possible to collect and share a massive amount of omics data, along with its associated metadata. Enhancing metadata availability is critical to ensure data reusability and reproducibility and to facilitate novel biomedical discoveries through effective data reuse. Yet, incomplete metadata accompanying public omics data may hinder reproducibility and reusability by reducing sample interpretability and limiting secondary analyses. In this study, we performed a comprehensive assessment of metadata completeness shared in both scientific publications and/or public repositories by analyzing over 253 studies encompassing over 164 thousands samples, including both human and non-human mammalian studies. We observed that studies often omit over a quarter of important phenotypes, with an average of only 74.8% of them shared either in the text of publication or the corresponding repository. Notably, public repositories alone contained 62% of the metadata, surpassing the textual content of publications by 3.5%. Only 11.5% of studies completely shared all phenotypes, while 37.9% shared less than 40% of the phenotypes. Studies involving non-human samples were more likely to share metadata than studies involving human samples. We observed similar results on the extended dataset spanning 2.1 million samples across over 61,000 studies from the Gene Expression Omnibus repository. The limited availability of metadata reported in our study emphasizes the necessity for improved metadata sharing practices and standardized reporting. Finally, we discuss the numerous benefits of improving the availability and quality of metadata to the scientific community and beyond, supporting data-driven decision-making and policy development in the field of biomedical research. This work provides a scalable framework for evaluating metadata availability and may help guide future policy and infrastructure development.
Open AccessThe systematic assessment of completeness of public metadata accompanying omics studies in the Gene Expression Omnibus
Recent advances in high-throughput sequencing technologies have made it possible to collect and share a massive amount of omics data, along with its associated metadata. Enhancing metadata availability is critical to ensure data reusability and reproducibility and to facilitate novel biomedical discoveries through effective data reuse. Yet, incomplete metadata accompanying public omics data may hinder reproducibility and reusability by reducing sample interpretability and limiting secondary analyses. In this study, we performed a comprehensive assessment of metadata completeness shared in both scientific publications and/or public repositories by analyzing over 253 studies encompassing over 164 thousands samples, including both human and non-human mammalian studies. We observed that studies often omit over a quarter of important phenotypes, with an average of only 74.8% of them shared either in the text of publication or the corresponding repository. Notably, public repositories alone contained 62% of the metadata, surpassing the textual content of publications by 3.5%. Only 11.5% of studies completely shared all phenotypes, while 37.9% shared less than 40% of the phenotypes. Studies involving non-human samples were more likely to share metadata than studies involving human samples. We observed similar results on the extended dataset spanning 2.1 million samples across over 61,000 studies from the Gene Expression Omnibus repository. The limited availability of metadata reported in our study emphasizes the necessity for improved metadata sharing practices and standardized reporting. Finally, we discuss the numerous benefits of improving the availability and quality of metadata to the scientific community and beyond, supporting data-driven decision-making and policy development in the field of biomedical research. This work provides a scalable framework for evaluating metadata availability and may help guide future policy and infrastructure development.